Core Insights - Viatris Inc. is experiencing continued operational growth, as evidenced by their recent third quarter earnings report, which reflects a strong foundation built on three strategic pillars introduced earlier this year [3]. Group 1: Company Overview - The CFO of Viatris, Doretta Mistras, expressed confidence in the company's position and the momentum being maintained through the execution of their strategic initiatives [3]. Group 2: Strategic Focus - The company has outlined three strategic pillars that are central to its operational growth and overall business strategy, which were reiterated during the conference [3].

Company and Industry Overview * **Company**: Viatris Inc. (NASDAQ: VTRS) * **Industry**: Pharmaceuticals, Healthcare Key Points and Arguments 1. **Strategic Pillars**: * **Diversified and Growing Base Business**: Demonstrated year-over-year operational adjusted revenue growth for six consecutive quarters, driven by both brands and generics. [4] * **Innovative Pipeline**: Executing clinical trials for selatogrel and cenerimod, and entered into an exclusive licensing agreement with Lexicon for sotagliflozin. [8] * **Capital Allocation**: 50% for business development, 25% for share repurchases, and 25% for dividends. [17] 2. **Financial Performance**: * Generated strong free cash flow of $866 million in Q3, bringing year-to-date cash flow generation to $1.9 billion. [7] * Repurchased about $1.9 billion of debt in Q3. [6] * Confident in generating $2.3 billion of cash flow on an ongoing basis. [7] 3. **New Product Revenue**: * On track to achieve $500 million to $600 million of new product revenue for the year. [5] * Pipeline includes generic launches in North America and Europe, as well as key complex generics like glucagon, liraglutide, and iron sucrose. [12] 4. **Regulatory Updates**: * Nearing the end of regulatory processes for sandostatin LAR, liraglutide, and iron sucrose. [14] * Meeting with FDA for GA Depot in December. [14] 5. **Capital Allocation Strategy**: * 50% of free cash flow allocated to business development, focusing on supporting the base business and adding innovative assets. [24] * Disciplined approach to evaluating business development opportunities, considering strategic fit, commercial potential, and financial impact. [29] 6. **Therapeutic Areas of Focus**: * Ophthalmology, GI, dermatology, cardiovascular, and immunology. [53] 7. **Geographical Focus**: * Europe, Greater China, emerging markets, and JANZ. [55] Additional Important Points * Viatris has a strong global footprint and expertise in both brands and generics. [55] * The company is focused on leveraging its existing infrastructure and capabilities to drive growth. [24] * Viatris is committed to being disciplined and thoughtful in its approach to business development. [29]

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups prior to co-founding 1200 Pharma at the California Institute of Technology (Caltech, 2016).-Became the first employee of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures)-Remains an avid investor, focused on market trends and especially biotechnology stocks ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other j ...

Viatris Inc. (VTRS) delivered third-quarter 2024 adjusted earnings of 75 cents per share, which beat the Zacks Consensus Estimate of 68 cents. The company recorded adjusted earnings of 79 cents per share in the year-ago quarter.Total revenues came in at $3.75 billion, down 4.8% year over year. Revenues included product sales and other revenues. The top line beat the Zacks Consensus Estimate of $3.68 billion.VTRS’ shares have risen 7.2% year to date against the industry’s 5.1% decline.Image Source: Zacks Inv ...

Q3 2024 Earnings November 7, 2024 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform A ...

Financial Data and Key Metrics Changes - Total revenues for Q3 2024 were reported at $3.8 billion, reflecting an operational revenue growth of approximately 3% year-over-year [8][22] - Adjusted EBITDA reached $1.3 billion, growing approximately 4% from the previous year [8][22] - Adjusted earnings per share (EPS) increased to $0.75, representing a growth of approximately 6% [8][22] - Free cash flow generated was $866 million, excluding transaction costs and taxes, marking a 10% increase [28][22] Business Line Data and Key Metrics Changes - The diversified base business grew by 3% year-over-year, marking the sixth consecutive quarter of operational revenue growth [22][24] - Brand performance increased by 2%, while Generics saw a growth of 4% [23][24] - New product revenues amounted to $133 million for the quarter, totaling $497 million year-to-date, with expectations to reach the higher end of the $500 million to $600 million range for the year [9][25] Market Data and Key Metrics Changes - In developed markets, net sales grew by approximately 3%, driven by the generics business [25] - Europe experienced a 6% growth, attributed to new products and strong generics performance [25] - North America saw a 5% growth in generics, while brand sales declined due to Medicaid utilization impacts [26] - Greater China reported a 3% growth, supported by strong volume growth across various channels [27] Company Strategy and Development Direction - The company is focused on capital allocation as a critical factor for optimizing shareholder value and driving future growth [10][11] - Plans for 2025 include more aggressive share buybacks, balanced with disciplined investments in commercialized or late-stage assets [11][12] - The company aims to leverage its global healthcare infrastructure to expand its innovative portfolio, particularly in cardiovascular disease [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the base business into 2025, with expectations of generating $450 million to $550 million in new product revenue annually [38][40] - The company is on track to achieve its long-term gross leverage target, with a focus on maintaining a leverage ratio of 2.8 to 3.2 times [30][29] - Management acknowledged potential challenges in the fourth quarter due to normal product seasonality and phasing of certain generic products [32][33] Other Important Information - The company repaid approximately $1.9 billion in debt, bringing total outstanding debt below $15 billion [29][22] - The adjusted gross margin remained stable at approximately 58.5%, with operating expenses flat compared to the prior year [28][22] Q&A Session Summary Question: Future new product revenue expectations - Management indicated that the base business is expected to continue generating momentum similar to the current year, with historical new product revenue contributions of $450 million to $550 million anticipated [38][40] Question: Capital allocation strategy and leverage targets - Achieving a leverage ratio of 3 times is crucial for the company to utilize $2.3 billion in free cash flow for shareholder returns and business development [39][40] Question: Regulatory environment in China - Management emphasized a strong compliance structure in China and maintained confidence in their operations despite external investigations affecting other companies [43] Question: Updates on product approvals - The company is scheduled to meet with the FDA regarding GA Depot in mid-December and expects to launch Sandostatin next year [44] Question: Future deal sizes and EBITDA expectations - Management clarified that future deals will focus on disciplined business development, targeting near-market assets, while not providing specific EBITDA guidance for 2025 [48][50] Question: Impact of ARV supply chain issues - Management acknowledged ongoing supply chain impacts on the ARV business but is working to address backlogs [57]

For the quarter ended September 2024, Viatris (VTRS) reported revenue of $3.75 billion, down 4.8% over the same period last year. EPS came in at $0.75, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of +1.89% over the Zacks Consensus Estimate of $3.68 billion. With the consensus EPS estimate being $0.68, the EPS surprise was +10.29%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.29%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.68 per share when it actually produced earnings of $0.69, delivering a surprise of 1.47%.Over the last four quarters, the company ...

Viatris Reports Third Quarter Financial Results for 2024 • Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] • Strong New Product Revenues of $133 Million Drove Growth Across Segments • U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a DivestitureAdjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted ...